Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $636000.0.

  • CytomX Therapeutics' Amortizatization of Intangibles fell 4786.89% to $636000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 6631.11%. This contributed to the annual value of $5.3 million for FY2024, which is 2841.35% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Amortizatization of Intangibles of $636000.0 as of Q3 2025, which was down 4786.89% from $397000.0 recorded in Q2 2025.
  • CytomX Therapeutics' 5-year Amortizatization of Intangibles high stood at $2.2 million for Q4 2023, and its period low was -$141000.0 during Q1 2021.
  • Its 5-year average for Amortizatization of Intangibles is $741631.6, with a median of $454000.0 in 2025.
  • In the last 5 years, CytomX Therapeutics' Amortizatization of Intangibles tumbled by 21102.36% in 2021 and then skyrocketed by 608333.33% in 2023.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Amortizatization of Intangibles stood at $15000.0 in 2021, then soared by 140.0% to $36000.0 in 2022, then skyrocketed by 6083.33% to $2.2 million in 2023, then plummeted by 64.65% to $787000.0 in 2024, then dropped by 19.19% to $636000.0 in 2025.
  • Its Amortizatization of Intangibles stands at $636000.0 for Q3 2025, versus $397000.0 for Q2 2025 and $454000.0 for Q1 2025.